148 related articles for article (PubMed ID: 28089723)
1. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
[TBL] [Abstract][Full Text] [Related]
2. Providing guidance for genomics-based cancer treatment decisions: insights from stakeholder engagement for post-prostatectomy radiation therapy.
Abe J; Lobo JM; Trifiletti DM; Showalter TN
BMC Med Inform Decis Mak; 2017 Aug; 17(1):128. PubMed ID: 28836985
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.
Lobo JM; Dicker AP; Buerki C; Daviconi E; Karnes RJ; Jenkins RB; Patel N; Den RB; Showalter TN
PLoS One; 2015; 10(3):e0116866. PubMed ID: 25837660
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant vs. salvage Radiation Therapy after Radical Prostatectomy: Role of Decipher® in the Era of Personalized Medicine.
Nowroozi A; Karimi A; Alilou S; Amini E
Urol J; 2021 Jan; 18(3):349-350. PubMed ID: 33423246
[TBL] [Abstract][Full Text] [Related]
5. Reconsidering adjuvant versus salvage radiation therapy for prostate cancer in the genomics era.
Lobo JM; Stukenborg GJ; Trifiletti DM; Patel N; Showalter TN
J Comp Eff Res; 2016 Jul; 5(4):375-82. PubMed ID: 27294829
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
Zubek VB; Konski A
Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
[TBL] [Abstract][Full Text] [Related]
7. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed.
Carter HE; Martin A; Schofield D; Duchesne G; Haworth A; Hornby C; Sidhom M; Jackson M
Radiother Oncol; 2014 Aug; 112(2):187-93. PubMed ID: 24929702
[TBL] [Abstract][Full Text] [Related]
8. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
Reed SD; Stewart SB; Scales CD; Moul JW
Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
[TBL] [Abstract][Full Text] [Related]
9. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
Den RB; Yousefi K; Trabulsi EJ; Abdollah F; Choeurng V; Feng FY; Dicker AP; Lallas CD; Gomella LG; Davicioni E; Karnes RJ
J Clin Oncol; 2015 Mar; 33(8):944-51. PubMed ID: 25667284
[TBL] [Abstract][Full Text] [Related]
10. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
11. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer.
Dorth JA; Lee WR; Chino J; Abouassaly R; Ellis RJ; Myers ER
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):383-390. PubMed ID: 29353655
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.
Roth JA; Ramsey SD; Carlson JJ
Oncologist; 2015 Dec; 20(12):1355-64. PubMed ID: 26482553
[TBL] [Abstract][Full Text] [Related]
14. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study.
Michalopoulos SN; Kella N; Payne R; Yohannes P; Singh A; Hettinger C; Yousefi K; Hornberger J;
Curr Med Res Opin; 2014 Aug; 30(8):1547-56. PubMed ID: 24803160
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer.
Chang EM; Punglia RS; Steinberg ML; Raldow AC
Urology; 2019 Apr; 126():89-95. PubMed ID: 30580007
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
Amin NP; Sher DJ; Konski AA
Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
[TBL] [Abstract][Full Text] [Related]
17. Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.
Boyd KA; Jones RJ; Paul J; Birrell F; Briggs AH; Leung HY
BMJ Open; 2015 Oct; 5(10):e007925. PubMed ID: 26482768
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
19. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
20. Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists.
Nguyen PL; Shin H; Yousefi K; Thompson DJ; Hornberger J; Hyatt AS; Badani KK; Morgan TM; Feng FY
Urology; 2015 Jul; 86(1):35-40. PubMed ID: 26142578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
